HYBRID EVENT: Join us in person in Tokyo, Japan or attend virtually from anywhere.
Progress in treating pediatric solid tumors has seen significant advancements in recent years, thanks to improvements in surgical techniques, radiation therapy, and the development of targeted therapies. Pediatric cancers, such as neuroblastoma, Wilms' tumor, and osteosarcoma, require specialized approaches due to the unique biology of childhood cancers and the long-term impact of treatments on growing bodies. New immunotherapies and targeted therapies offer promising options for children with solid tumors, focusing on the specific molecular drivers of cancer. These innovations aim to improve survival rates while minimizing the long-term side effects of treatments, such as developmental delays, infertility, and secondary cancers, providing children with better quality of life and long-term outcomes.
